摘要背景除了可以降解胰高血糖素肽‐1 (GLP‐1), 二肽基肽酶‐4 (DPP‐4) 还可以灭活几种趋化
因子, 包括间质细胞衍生因子‐1α (stromal cell‐derived factor‐1α, SDF‐1α) …

Aims Following myocardial infarction (MI), individuals with diabetes have a two‐fold
increase in the risk of heart failure, due in part to excessive loss of cardiac microvasculature …

Cardiovascular diseases (CVD) are still the prevailing cause of death not only in
industrialized countries, but even worldwide. Type 2 diabetes mellitus (type 2 DM) and …

Abstract Dipeptidyl peptidase-4 (DPP-4) inhibitors not only improve impaired glucose
tolerance in diabetes, but also have pleiotropic extra-pancreatic effects such as …

Abstract Dipeptidyl peptidase-4 (DPP-4), glycyl-prolyl-naphthylamidase, is a serine protease
that catalyzes the hydrolysis of various proline-containing polypeptides. It is involved in the …

BACKGROUND: Dipeptidylpeptidase-4 inhibition is reported to have beneficial effects on
myocardial ischemia. Mechanisms might include a reduced degradation of stromal cell …

The aim of our study was to assess and compare the effects of dipeptidyl peptidase 4
(DPP4) inhibitors, saxagliptin and sitagliptin, on metabolic control of disease and cardiac …

Drugs that inhibit dipeptidyl peptidase-4 (DPP-4) are conventionally regarded as incretin-
based agents that signal through the glucagon-like peptide-1 (GLP-1) receptor. However …

Aims We examined whether, in diabetic Ob/Ob mice, the dipeptidyl peptidase-4 (DPP-4)
inhibitor (PKF275-055), an antihyperglycemic drug, that inhibits the biological inactivation of …

Abstract Dipeptidyl peptidase-4 (DPP4) enzyme inhibition has been reported to increase
plasma glucagon-like peptide-1 (GLP-1) level for controlling postprandial glucose …